Ian W. Taylor

9.0k citations

88 papers · 7.5k indexed · 3 hit papers · h-index 38

Molecular Biology top 2%
Oncology top 1%
Cancer Research top 0.5%
Pulmonary and Respiratory Medicine top 1%
Pathology and Forensic Medicine top 1%

Co-authors: David W. Hedley Michael Friedländer Catherine A. Rugg Elizabeth A. Musgrove Robert L. Sutherland Jeffrey L. Wrana Rosemary E. Hall Yongmei Liu
Topics: Lung Cancer Treatments and Mutations (18 papers)Colorectal Cancer Treatments and Studies (16 papers)Cancer Genomics and Diagnostics (12 papers)
Cited by: Cancer Research Oncology Pathology and Forensic Medicine
Journals: Science Cell Journal of Clinical Oncology
Partner nations: United Kingdom Australia United States

In The Last Decade

Ian W. Taylor

87 papers receiving 7.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

1983 1.8k citations Ian W. Taylor et al. profile →
High-Throughput Mapping of a Dynamic Signaling Network in Mammalian Cells

2005 553 citations Miriam Barrios‐Rodiles, Kevin R. Brown et al. Science profile →
Dynamic modularity in protein interaction networks predicts breast cancer outcome

2009 544 citations Ian W. Taylor, Yongmei Liu et al. profile →

Peers

Countries citing papers authored by Ian W. Taylor

Since Specialization

Citations

This map shows the geographic impact of Ian W. Taylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian W. Taylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian W. Taylor more than expected).

Fields of papers citing papers by Ian W. Taylor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian W. Taylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian W. Taylor. The network helps show where Ian W. Taylor may publish in the future.

Co-authorship network of co-authors of Ian W. Taylor

This figure shows the co-authorship network connecting the top 25 collaborators of Ian W. Taylor. A scholar is included among the top collaborators of Ian W. Taylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian W. Taylor. Ian W. Taylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increasing HD-BIOP3 Seeding Efficiencies Using the VIPS™ 2019 ·Genetic Engineering & Biotechnology News ·(unknown),Amanda Holmes,(unknown),(unknown),Ian W. Taylor	1
2	Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials 2016 ·Annals of Oncology ·Sundar Ramalingam,Kenneth J. O’Byrne,Michael Boyer,Tony Mok,Pasi A. Jänne,Hui Zhang,(unknown),Ian W. Taylor,Eric Sbar,(unknown)	48
3	Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors 2015 ·Annals of Oncology ·Mark G. Kris,D. Ross Camidge,Giuseppe Giaccone,Toyoaki Hida,Bob T. Li,Joseph O’Connell,Ian W. Taylor,(unknown),Maria E. Arcila,Zelanna Goldberg,Pasi A. Jänne	221
4	Paradigm Shift for Cell-Line Development 2015 ·Genetic Engineering & Biotechnology News ·(unknown),Ian W. Taylor	2
5	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial 2014 ·The Lancet Oncology ·Suresh S. Ramalingam,Pasi A. Jänne,Tony Mok,Kenneth J. O’Byrne,Michael Boyer,Joachim von Pawel,Adam Płużański,Mikhail Shtivelband,Lara Iglesias Docampo,Jaafar Bennouna,Hui Zhang,Jane Liang,Jim Doherty,Ian W. Taylor,(unknown),Zelanna Goldberg,Joseph O’Connell,Luis Paz‐Ares	111
6	Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009). 2014 ·Journal of Clinical Oncology ·Suresh S. Ramalingam,Pasi A. Jänne,Tony Mok,Kenneth J. O’Byrne,Michael Boyer,Hui Zhang,Jane Liang,Jim Doherty,Ian W. Taylor,(unknown),Joseph O’Connell,Luis Paz‐Ares	13
7	Potential Predictive Markers of Efficacy of Dacomitinib in Patients with Recurrent/Metastatic Scchn from a Phase 2 Trial 2013 ·Annals of Oncology ·Denis Soulières,Ghassan Allo,(unknown),(unknown),(unknown),(unknown),Susan Quinn,Ian W. Taylor,Patricia A. English,Lillian L. Siu	1
8	Protein interaction networks in medicine and disease 2012 ·PROTEOMICS ·Ian W. Taylor,Jeffrey L. Wrana	41
9	High-Throughput Mapping of a Dynamic Signaling Network in Mammalian Cellsbreakdown → 2005 ·Science ·Miriam Barrios‐Rodiles,Kevin R. Brown,Barish Ozdamar,Rohit Bose,Zhong Liu,(unknown),Fukiko Shinjo,Yongmei Liu,Joanna Dembowy,Ian W. Taylor,Valbona Luga,Nataša Pržulj,Mark D. Robinson,Harukazu Suzuki,Yoshihide Hayashizaki,Igor Jurišica,Jeffrey L. Wrana	553
10	Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18 FDG and 18 FLT PET 2004 ·European Journal of Nuclear Medicine and Molecular Imaging ·D. Francis,Dimitris Visvikis,Durval C. Costa,(unknown),Tan Arulampalam,S. K. Luthra,Ian W. Taylor,P. J. Ell	15
11	Quantitative comparison of 18FDG and 18FLT in colorectal carcinoma 2002 ·UCL Discovery (University College London) ·Dimitris Visvikis,(unknown),Durval C. Costa,(unknown),(unknown),Ian W. Taylor,PJ Ell	2
12	Identification of in Vitro Folding Conditions for Procathepsin S and Cathepsin S Using Fractional Factorial Screens 2002 ·Protein Expression and Purification ·(unknown),Brian Middleton,Stephanie Raines,M. Needham,Ian W. Taylor,(unknown),W. Mark Abbott	42
13	Study of the interaction of the medium chain μ2 subunit of the clathrin-associated adapter protein complex 2 with cytotoxic T-lymphocyte antigen 4 and CD28 2001 ·Biochemical Journal ·(unknown),Jane McPheat,Claire A. Minshull,Nel C. Moore,Richard A. Pauptit,Siân Rowsell,(unknown),(unknown),Ian W. Taylor,W. Mark Abbott	18
14	Refolding, Purification, and Characterization of a Loop Deletion Mutant of Human Bcl-2 from Bacterial Inclusion Bodies 1999 ·Protein Expression and Purification ·Malcolm Anderson,David P. Blowers,Neil Hewitt,Philip Hedge,Alexander L. Breeze,(unknown),Ian W. Taylor	17
15	Crystal structure of the anti-fungal target N-myristoyl transferase 1998 ·Nature Structural Biology ·Simon A. Weston,Roger Camble,(unknown),(unknown),Ian W. Taylor,Mark Egerton,Alec D. Tucker,Alan Riboldi‐Tunnicliffe,Anil Mistry,Filippo Mancia,Eric de La Fortelle,John J. Irwin,G. Bricogne,Richard A. Pauptit	93
16	Cloning and Expression of Cytosolic Phospholipase A₂ (cPLA₂) and a Naturally Occurring Variant 1996 ·European Journal of Biochemistry ·Robert D. Gordon,Ian Leighton,David G. Campbell,Philip Cohen,(unknown),David C. Wilton,(unknown),(unknown),Richard Mott,Ian W. Taylor,(unknown),(unknown),John Morten,M. Needham	19
17	Analytical DNA flow cytometric analysis of deoxyadenosine toxicity in cultured human leukemic lymphoblasts. 1984 ·Molecular Pharmacology ·(unknown),E. Tripp,Ian W. Taylor	3
18	Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. 1983 ·PubMed ·Robert L. Sutherland,Rosemary E. Hall,Ian W. Taylor	243
19	Alginate Biosynthesis by Pseudomonas mendocina 1983 ·Microbiology ·Andrew J. Hacking,Ian W. Taylor,T. R. Jarman,John R. W. Govan	40
20	G1-phase arrest of cultured human leukemic T-cells induced by deoxyadenosine. 1981 ·PubMed ·Richard M. Fox,Richard Kefford,E. Tripp,Ian W. Taylor	48

About Ian W. Taylor

Ian W. Taylor is a scholar working on Oncology, Cancer Research and Molecular Biology, having authored 88 papers that have together received 7.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (18 papers), Colorectal Cancer Treatments and Studies (16 papers) and Cancer Genomics and Diagnostics (12 papers). The work is most often cited by research in Cancer Research (1.8k citations), Oncology (2.4k citations) and Pathology and Forensic Medicine (1.1k citations). Ian W. Taylor has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include David W. Hedley, Michael Friedländer, Catherine A. Rugg, Elizabeth A. Musgrove, Robert L. Sutherland, Jeffrey L. Wrana, Rosemary E. Hall, Yongmei Liu, Bruce Milthorpe and Joseph O’Connell. Their work appears in journals such as Science, Cell and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact